Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,858 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
Kellerer M, Kaltoft MS, Lawson J, Nielsen LL, Strojek K, Tabak Ö, Jacob S. Kellerer M, et al. Among authors: lawson j. Diabetes Obes Metab. 2022 Sep;24(9):1788-1799. doi: 10.1111/dom.14765. Epub 2022 Jun 29. Diabetes Obes Metab. 2022. PMID: 35546450 Free PMC article. Clinical Trial.
A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease.
Evans LM, Mellbin L, Johansen P, Lawson J, Paine A, Sandberg A. Evans LM, et al. Among authors: lawson j. Endocrinol Diabetes Metab. 2021 May 15;4(3):e00259. doi: 10.1002/edm2.259. eCollection 2021 Jul. Endocrinol Diabetes Metab. 2021. PMID: 34277983 Free PMC article.
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
Schechter M, Melzer Cohen C, Fishkin A, Rozenberg A, Yanuv I, Sehtman-Shachar DR, Chodick G, Clark A, Abrahamsen TJ, Lawson J, Karasik A, Mosenzon O. Schechter M, et al. Among authors: lawson j. Cardiovasc Diabetol. 2023 May 27;22(1):126. doi: 10.1186/s12933-023-01829-0. Cardiovasc Diabetol. 2023. PMID: 37244998 Free PMC article.
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL, Idorn T, Lawson J, Mahaffey KW, Mann JFE, Mersebach H, Perkovic V, Tuttle K, Pratley R. Rossing P, et al. Among authors: lawson j. Nephrol Dial Transplant. 2023 Aug 31;38(9):2041-2051. doi: 10.1093/ndt/gfad009. Nephrol Dial Transplant. 2023. PMID: 36651820 Free PMC article. Clinical Trial.
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials.
Heerspink HJL, Apperloo E, Davies M, Dicker D, Kandler K, Rosenstock J, Sørrig R, Lawson J, Zeuthen N, Cherney D. Heerspink HJL, et al. Among authors: lawson j. Diabetes Care. 2023 Apr 1;46(4):801-810. doi: 10.2337/dc22-1889. Diabetes Care. 2023. PMID: 36801984 Free PMC article.
1,858 results